Literature DB >> 2601542

Nasal polyps: epithelium and goblet cell density.

P L Larsen1, M Tos.   

Abstract

The density of goblet cells was determined in 14 anterior and 15 posterior nasal polyps using the whole-mount method. The specimens were then serial cut and the type of epithelium was determined in nine localities in each polyp. The goblet cell density was correlated to the epithelial type. Pseudostratified, cylindrical epithelium was the prevailing type, occurring in 62% of anterior localities and 78% of posterior localities. Transitional types of epithelium were found in 33% of the anterior and 19% of the posterior localities. Stratified squamous epithelium occurred in 5% and 3%, respectively. The goblet cell density was highest in hyperplastic pseudostratified epithelium, whereas it was four times lower in transitional epithelium and even lower in squamous epithelium. Marked differences in the distribution of epithelium and goblet cell density were found between anterior and posterior polyps, illustrating that the epithelium constantly changes under the influence of air current, contact with other polyps, infection, growth, and age of the polyp as well as other unknown factors.

Entities:  

Mesh:

Year:  1989        PMID: 2601542     DOI: 10.1288/00005537-198912000-00012

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  3 in total

Review 1.  Nasal polyposis, eosinophil dominated inflammation, and allergy.

Authors:  N Mygind; R Dahl; C Bachert
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  Surgical versus medical interventions in CRS and nasal polyps: comparative evidence between medical and surgical efficacy.

Authors:  Osama Dessouky; Claire Hopkins
Journal:  Curr Allergy Asthma Rep       Date:  2015-11       Impact factor: 4.806

3.  The analysis of RCAS1 and DFF-45 expression in nasal polyps with respect to immune cells infiltration.

Authors:  Magdalena Dutsch-Wicherek; Romana Tomaszewska; Pawel Strek; Lukasz Wicherek; Jacek Skladzien
Journal:  BMC Immunol       Date:  2006-03-21       Impact factor: 3.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.